Promoter mutations were found to correlate with expression in cancer samples for PLEKHS1,3SDHD,2BCL2, MYC, CD83, and WWOX. 13 Melton et al. additionally identified mutations near GP6 and between SETD3 and BCL11B that reduced expression in cellular assays.2 Negative correlation with survival was observed for promoter mutations in SDHD3 and RBM513 for melanoma patients. This evidence concerns the gene MYC and cancer.